Samira Asadollahi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samira Asadollahi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Fateme Sefid
Department of Molecular Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd 8916978477, Iran
2 shared publications - Seyed Mehdi Kalantar
Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 shared publications - Fatemeh Aghaeimeybodi
Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
1 shared publication - Fatemeh Soltani
Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
1 shared publication - Hamed Ghoshouni
Cardiovascular Epidemiology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran
1 shared publication - Hossein Hozhabri
Department of Experimental Medicine, Sapienza University, Rome, Italy, uniroma1.it
1 shared publication
Latest Publications
- 16 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1729
A novel de novo variant of CDKL5 in an Iranian child with infantile-onset refractory epilepsy
Background Epilepsy is defined as a long-term brain disease with recurrent and spontaneous seizures that often begin in childhood and encompass a wide range of etiologies, including genetic factors. This study aimed to identify and characterize the genetic cause underlying developmental delay and refractory epilepsy in an Iranian patient. Methods We performed a prospective evaluation of an Iranian girl presenting with developmental delay, refractory seizures, and hypotonia. The case was referred to the Genetic Research Center, Meybod,, Iran. Whole exome sequencing and Sanger sequencing were performed to identify the disease-causing variant and validate it, respectively. Also, bioinformatic analyses were used to evaluate the predicted pathogenicity and structural consequences of the variants. Results A novel de novo frameshift variant in CDKL5 gene (c.1037_1038delTCinsCAGATCTAA, p.Ile346Thrfs*14) was identified and classified as pathogenic based on ACMG criteria. The variant is predicted to engender a premature stop codon, leading to extensive shortening of the protein and loss of essential functional domains. Additionally, Valproate-Lamotrigine combination therapy resulted in significant clinical effects, such as a considerable reduction in the number of seizures. Conclusion The present study can expand the mutational spectrum of CDKL5 and highlight the clinical advantage of sequencing-based genetic testing for early diagnosis and personalized therapeutic management of refractory epilepsy.
- 16 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1729
A novel de novo variant of CDKL5 in an Iranian child with infantile-onset refractory epilepsy
Background Epilepsy is defined as a long-term brain disease with recurrent and spontaneous seizures that often begin in childhood and encompass a wide range of etiologies, including genetic factors. This study aimed to identify and characterize the genetic cause underlying developmental delay and refractory epilepsy in an Iranian patient. Methods We performed a prospective evaluation of an Iranian girl presenting with developmental delay, refractory seizures, and hypotonia. The case was referred to the Genetic Research Center, Meybod,, Iran. Whole exome sequencing and Sanger sequencing were performed to identify the disease-causing variant and validate it, respectively. Also, bioinformatic analyses were used to evaluate the predicted pathogenicity and structural consequences of the variants. Results A novel de novo frameshift variant in CDKL5 gene (c.1037_1038delTCinsCAGATCTAA, p.Ile346Thrfs*14) was identified and classified as pathogenic based on ACMG criteria. The variant is predicted to engender a premature stop codon, leading to extensive shortening of the protein and loss of essential functional domains. Additionally, Valproate-Lamotrigine combination therapy resulted in significant clinical effects, such as a considerable reduction in the number of seizures. Conclusion The present study can expand the mutational spectrum of CDKL5 and highlight the clinical advantage of sequencing-based genetic testing for early diagnosis and personalized therapeutic management of refractory epilepsy.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Genetic Characterization of MODY in Iranian Families Using Multigenerational‐Based Whole‐Exome Sequencing Approach
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Open AccessGenetic Characterization of MODY in Iranian Families Using Multigenerational‐Based Whole‐Exome Sequencing Approach
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.
- Open Access
- 16 October 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-11
Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19. In this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020–2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All participants were genotyped using RFLP-PCR. Different genotypes of FCGR2A rs1801274 and IL-6R rs2228145 were compared in terms of the recovery process. 43.2% of patients were male and 56.8% were female with an average age of 58.20(± 16.214) years. The GA genotype for FCGR2A rs1801274 increased the risk of death (OR = 2.83, P = 0.038) and ventilation (OR = 2.71, P = 0.047) in TCZ-treated individuals. However, there was no risk of death and ventilation with IL-6R rs2228145 (P > 0.05). Additionally, docking analysis showed that not only IL6R but also FCGR2A can be a ligand for TCZ. This study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes.
- 16 October 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-11
Open AccessImpact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19. In this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020–2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All participants were genotyped using RFLP-PCR. Different genotypes of FCGR2A rs1801274 and IL-6R rs2228145 were compared in terms of the recovery process. 43.2% of patients were male and 56.8% were female with an average age of 58.20(± 16.214) years. The GA genotype for FCGR2A rs1801274 increased the risk of death (OR = 2.83, P = 0.038) and ventilation (OR = 2.71, P = 0.047) in TCZ-treated individuals. However, there was no risk of death and ventilation with IL-6R rs2228145 (P > 0.05). Additionally, docking analysis showed that not only IL6R but also FCGR2A can be a ligand for TCZ. This study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes.